Anticoagulation in pulmonary arterial hypertension - association with mortality, healthcare utilization, and quality of life: The Pulmonary Hypertension Association Registry (PHAR).

Routine long-term anticoagulation in PAH is controversial and shown to be beneficial or neutral in idiopathic disease (IPAH) and neutral-to-harmful in connective tissue disease (CTD-PAH). Authors sought examined the association between anticoagulation and mortality, healthcare utilization, and quality of life (QoL) in PAH using PHAR data. Anticoagulation was not associated with higher mortality, but is associated with increased healthcare utilization in the PHAR. PAH-specific QoL may be worse in patients receiving anticoagulation.